Country: United States
Language: English
Source: NLM (National Library of Medicine)
theophylline anhydrous (UNII: 0I55128JYK) (theophylline anhydrous - UNII:0I55128JYK)
Purdue Pharmaceutical Products LP
theophylline anhydrous
theophylline anhydrous 400 mg
ORAL
PRESCRIPTION DRUG
Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. Uniphyl® is contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.
Uniphyl® (theophylline, anhydrous) Controlled-Release Tablets 400 mg are supplied in white, opaque plastic, child-resistant bottles containing 100 tablets (NDC 67781-251-01) or 500 tablets (NDC 67781-251-05). Each round, white 400 mg tablet bears the symbol PF on the scored side and U400 on the other side. Uniphyl® (theophylline, anhydrous) Controlled-Release Tablets 600 mg are supplied in white, opaque plastic, child-resistant bottles containing 100 tablets (NDC 67781-252-01). Each rectangular, concave, white 600 mg tablet bears the symbol PF on the scored side and U 600 on the other side. Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F). Dispense in a tight, light-resistant container.
Abbreviated New Drug Application
UNIPHYL- THEOPHYLLINE ANHYDROUS TABLET PURDUE PHARMACEUTICAL PRODUCTS LP ---------- UNIPHYL TABLETS (THEOPHYLLINE, ANHYDROUS) 400 MG AND 600 MG UNICONTIN CONTROLLED-RELEASE SYSTEM DESCRIPTION Uniphyl (theophylline, anhydrous) Tablets in a controlled-release system allows a 24-hour dosing interval for appropriate patients. Theophylline is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste. Anhydrous theophylline has the chemical name 1H-Purine-2,6-dione, 3,7- dihydro-1,3-dimethyl-, and is represented by the following structural formula: The molecular formula of anhydrous theophylline is C H N O with a molecular weight of 180.17. Each controlled-release tablet for oral administration, contains 400 or 600 mg of anhydrous theophylline. Inactive Ingredients: cetostearyl alcohol, hydroxyethyl cellulose, magnesium stearate, povidone and talc. CLINICAL PHARMACOLOGY MECHANISM OF ACTION Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth muscle relaxation (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator prophylactic effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilatation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while non-bronchodilator prophylactic actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with theophylline appear to be mediated by inhibition of PDE III (e.g., hypotension, tachycardia, headache, and emesis) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow). Theophylline increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an adenosine-mediated cha Read the complete document